Genital Herpes News and Research

RSS

Anti-viral drug development programs progress successfully, reports NanoViricides

NanoViricides, Inc. (the "Company"), reports that the Company is well financed and its game changing anti-viral drug development programs are progressing successfully. As such, Management knows of no reason for the recent decline in stock price and associated volatility.

26 Oct 2009

Study reveals that older widowers are likely to be diagnosed with a STD

Widowers take care: Older men who have recently lost their wives are more likely than still-married peers to be diagnosed with a sexually transmitted disease (STD), according to a new study.

18 Sep 2009

NanoViricides' drug pipeline to be discussed at NanoBusiness2009

NanoViricides, Inc. (the "Company"), announced today that Anil Diwan, PhD, President of the Company has been asked to present a talk at NanoBusiness2009 - the 8th annual NanoBusiness Conference.

8 Sep 2009

Condoms reduce risk of herpes simplex virus 2

Condom use is associated with a reduced risk of contracting herpes simplex virus 2, according to a report based on pooled analysis of data from previous studies in the July 13 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

2 Sep 2009

Nanoviricides herpes study discussed on CBS News report

NanoViricides, Inc. (OTC BB: NNVC.OB), reported today that the CBS affiliate TV station WBRZ interviewed Professor K. Gus Kousoulas , PhD, in which he explained the potential implications of the Company’s nanoviricides™ anti-Herpes drug candidates.

12 Aug 2009

Nanoviricides anti-herpes drug candidate reduces viral load by 99.99%

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), has announced that the herpes simplex viral load was reduced by 99.99% or 10,000 fold in in-vitro studies by nanoviricides™ drug candidates.

10 Aug 2009

New research helps explain why treated genital herpes sores boost risk of HIV infection

New research helps explain why infection with herpes simplex virus-2 (HSV-2), which causes genital herpes, increases the risk for HIV infection even after successful treatment heals the genital skin sores and breaks that often result from HSV-2.

3 Aug 2009

Births by Cesarean section rose by more than 40 percent in 10 years

The percentage of pregnant women undergoing a repeat Cesarean section (C-section) delivery jumped from 65 percent to 90 percent between 1997 and 2006, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

16 Apr 2009

Male circumcision reduces risk of herpes simplex virus type 2 and human papillomavirus

Heterosexual men who undergo medical circumcision can significantly reduce their risk of acquiring two common sexually transmitted infections - herpes simplex virus type 2 (HSV-2), the cause of genital herpes, and human papillomavirus (HPV), which can cause cancer and genital warts, according to a report in the March 26 issue of the New England Journal of Medicine (NEJM).

26 Mar 2009

ViroPharma reports results of trial for Maribavir in bone marrow transplant patients

ViroPharma Incorporated has announced that its Phase 3 trial evaluating maribavir used as prophylaxis in allogeneic stem cell, or bone marrow, transplant (SCT) patients did not achieve its primary endpoint.

10 Feb 2009

Gene-targeting approach for herpes treatment

A new therapy being developed at the University of Florida could, in time, produce another weapon for the fight against herpes.

3 Feb 2009

Topical microbicide protects against genital herpes

A topical microbicide that silences two genes can safely protect against genital herpes infection for as long as one week, according to a joint study by researchers at the Albert Einstein College of Medicine of Yeshiva University and Harvard Medical School.

21 Jan 2009

Starpharma's VivaGelR patent approved in Japan

Starpharma Holdings Limited today announced that one of its key patents relating to the use of dendrimers to protect against sexually transmitted infections has been approved in Japan.

29 Oct 2008

Deadly virus scrumpox a threat to rugby players wrestlers

Rugby players and wrestlers may be at risk of a potentially serious skin disease called "scrumpox".

29 Sep 2008

Herpes drug Acyclovir could help control HIV

Acyclovir -- a low-cost, generic drug used to treat herpes -- also might help control HIV in people living with both viruses, according to a study published Wednesday in the journal ell Host and Microbe, Reuters reports.

15 Sep 2008

Starpharma, SSL International reach marketing agreement over VivaGel condoms

The Australia-based Starpharma on Tuesday announced that its VivaGel-coated condom will be sold by SSL International, the owner of the Durex condom brand, Bloomberg reports.

11 Sep 2008

Herpes virus changes anti-herpes drug acyclovir to form that hinders AIDS virus

The drug acyclovir has long been used to suppress outbreaks of oral and genital herpes. Herpes viruses change acyclovir to a form that prevents them from reproducing.

10 Sep 2008

VivaGel coated condoms - Starpharma and SSL International in business

Starpharma Holdings Limited has announced that a full licence agreement has been signed with SSL International plc in relation to the VivaGel coated condom. SSL manufactures and sells Durex condoms, the market-leading condom brand worldwide.

9 Sep 2008

Experts say male circumcision the key to beating AIDS

Experts say while no cure or vaccine for AIDS exists male circumcision could be the key to driving the epidemic into a declining state and closer to extinction.

5 Aug 2008

Antiretroviral therapy as an aid to HIV prevention

The widespread use of highly active antiretroviral therapy may reduce the incidence of HIV in individuals and populations but has been overlooked by public health as a prevention strategy, write Dr. Julio Montaner and colleagues in the Canadian Medical Association Journal.

30 Jun 2008